Literature DB >> 22125073

Rapamycin-induced enhancement of vaccine efficacy in mice.

Chinnaswamy Jagannath1, Pearl Bakhru.   

Abstract

Th1 immunity protects against tuberculosis infection in mice and humans. The widely used BCG vaccine primes CD4 and CD8 T cells through signaling mechanisms from dendritic cells and macrophages. The latter express MHC-II and MHC-I molecules through which peptides from BCG vaccine are presented to CD4 and CD8 T cells, respectively. Since BCG sequesters within a phagosome that does not fuse with lysosomes, generation of peptides within antigen-presenting cells infected with BCG occurs with reduced efficiency. We demonstrate that activation of DCs containing BCG vaccine with rapamycin leads to an enhanced ability of DC vaccines to immunize mice against tuberculosis. Coadministration of rapamycin with BCG vaccine also enhanced Th1 immunity. We propose that rapamycin-mediated increase in Th1 responses offers novel models to study mTOR-mediated regulation of immunity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22125073      PMCID: PMC3387998          DOI: 10.1007/978-1-61779-430-8_18

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  13 in total

Review 1.  Mycobacterium tuberculosis phagosome.

Authors:  V Deretic; R A Fratti
Journal:  Mol Microbiol       Date:  1999-03       Impact factor: 3.501

Review 2.  Mycobacterium tuberculosis: here today, and here tomorrow.

Authors:  D G Russell
Journal:  Nat Rev Mol Cell Biol       Date:  2001-08       Impact factor: 94.444

3.  Rapamycin prolongs susceptibility of responding T cells to tolerance induction by CD8+ veto cells.

Authors:  Kimberly M Anderson; James C Zimring
Journal:  Transplantation       Date:  2006-01-15       Impact factor: 4.939

4.  Processing and presentation of a mycobacterial antigen 85B epitope by murine macrophages is dependent on the phagosomal acquisition of vacuolar proton ATPase and in situ activation of cathepsin D.

Authors:  Christopher R Singh; Rachel A Moulton; Lisa Y Armitige; Akhil Bidani; Mark Snuggs; Subramanian Dhandayuthapani; Robert L Hunter; Chinnaswamy Jagannath
Journal:  J Immunol       Date:  2006-09-01       Impact factor: 5.422

5.  Cutting edge: Rapamycin augments pathogen-specific but not graft-reactive CD8+ T cell responses.

Authors:  Ivana R Ferrer; Maylene E Wagener; Jennifer M Robertson; Alexa P Turner; Koichi Araki; Rafi Ahmed; Allan D Kirk; Christian P Larsen; Mandy L Ford
Journal:  J Immunol       Date:  2010-07-14       Impact factor: 5.422

Review 6.  The multifunctional role of mTOR in innate immunity: implications for transplant immunity.

Authors:  M D Säemann; M Haidinger; M Hecking; W H Hörl; T Weichhart
Journal:  Am J Transplant       Date:  2009-09-25       Impact factor: 8.086

7.  Mycobacterium bovis bacillus Calmette-Guérin secreting active cathepsin S stimulates expression of mature MHC class II molecules and antigen presentation in human macrophages.

Authors:  Hafid Soualhine; Ala-Eddine Deghmane; Jim Sun; Karen Mak; Amina Talal; Yossef Av-Gay; Zakaria Hmama
Journal:  J Immunol       Date:  2007-10-15       Impact factor: 5.422

8.  The effect of rapamycin on T cell development in mice.

Authors:  H Luo; W Duguid; H Chen; M Maheu; J Wu
Journal:  Eur J Immunol       Date:  1994-03       Impact factor: 5.532

9.  The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin.

Authors:  Rajesh R Rao; Qingsheng Li; Kunle Odunsi; Protul A Shrikant
Journal:  Immunity       Date:  2010-01-07       Impact factor: 31.745

10.  The Mycobacterium tuberculosis phagosome interacts with early endosomes and is accessible to exogenously administered transferrin.

Authors:  D L Clemens; M A Horwitz
Journal:  J Exp Med       Date:  1996-10-01       Impact factor: 14.307

View more
  24 in total

1.  mTOR regulates TLR-induced c-fos and Th1 responses to HBV and HCV vaccines.

Authors:  Li He; Aiping Zang; Min Du; Dapeng Ma; Chuanping Yuan; Chun Zhou; Jing Mu; Huanjing Shi; Dapeng Li; Xulin Huang; Qiang Deng; Jianhua Xiao; Huimin Yan; Lijian Hui; Ke Lan; Sidong Xiong; Xiaoxia Li; Zhong Huang; Hui Xiao
Journal:  Virol Sin       Date:  2015-06-11       Impact factor: 4.327

Review 2.  Trial Watch: Toll-like receptor agonists in cancer immunotherapy.

Authors:  Melody Smith; Elena García-Martínez; Michael R Pitter; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-10-11       Impact factor: 8.110

3.  mTOR inhibitors for treatment of low-risk prostate cancer.

Authors:  Michael A Liss; Lanette Rickborn; John DiGiovanni; Dean Bacich; Linda A DeGraffenried; Manish Parihar; Ian M Thompson; Zelton Dave Sharp
Journal:  Med Hypotheses       Date:  2018-06-05       Impact factor: 1.538

Review 4.  Fighting the SARS-CoV-2 pandemic requires a global approach to understanding the heterogeneity of vaccine responses.

Authors:  Jeffrey A Tomalka; Mehul S Suthar; Steven G Deeks; Rafick Pierre Sekaly
Journal:  Nat Immunol       Date:  2022-02-24       Impact factor: 31.250

Review 5.  mTOR is a key modulator of ageing and age-related disease.

Authors:  Simon C Johnson; Peter S Rabinovitch; Matt Kaeberlein
Journal:  Nature       Date:  2013-01-17       Impact factor: 49.962

Review 6.  Immune Cell Regulatory Pathways Unexplored as Host-Directed Therapeutic Targets for Mycobacterium tuberculosis: An Opportunity to Apply Precision Medicine Innovations to Infectious Diseases.

Authors:  Robert N Mahon; Richard Hafner
Journal:  Clin Infect Dis       Date:  2015-10-15       Impact factor: 9.079

7.  Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies.

Authors:  Edward Rockenstein; Gary Ostroff; Fusun Dikengil; Florentina Rus; Michael Mante; Jazmin Florio; Anthony Adame; Ivy Trinh; Changyoun Kim; Cassia Overk; Eliezer Masliah; Robert A Rissman
Journal:  J Neurosci       Date:  2017-12-15       Impact factor: 6.167

8.  Human monocyte-derived macrophage responses to M. tuberculosis differ by the host's tuberculosis, diabetes or obesity status, and are enhanced by rapamycin.

Authors:  Blanca I Restrepo; Arshad Khan; Vipul K Singh; Génesis P Aguillón-Durán; Eder Ledezma-Campos; David H Canaday; Chinnaswamy Jagannath
Journal:  Tuberculosis (Edinb)       Date:  2020-12-30       Impact factor: 2.973

9.  γδ T Cells Support Antigen-Specific αβ T cell-Mediated Antitumor Responses during BCG Treatment for Bladder Cancer.

Authors:  Niannian Ji; Neelam Mukherjee; Zhen-Ju Shu; Ryan M Reyes; Joshua J Meeks; David J McConkey; Jonathan A Gelfond; Tyler J Curiel; Robert S Svatek
Journal:  Cancer Immunol Res       Date:  2021-10-04       Impact factor: 12.020

10.  Rapamycin Improves the Response of Effector and Memory CD8+ T Cells Induced by Immunization With ASP2 of Trypanosoma cruzi.

Authors:  Barbara Ferri Moraschi; Isaú Henrique Noronha; Camila Pontes Ferreira; Leonardo M Cariste; Caroline B Monteiro; Priscila Denapoli; Talita Vrechi; Gustavo J S Pereira; Ricardo T Gazzinelli; Joseli Lannes-Vieira; Maurício M Rodrigues; Karina R Bortoluci; José Ronnie C Vasconcelos
Journal:  Front Cell Infect Microbiol       Date:  2021-05-25       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.